Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation

Next Previous
Trial Profile

A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Cytarabine (Primary) ; Olutasidenib (Primary) ; Decitabine; Dinaciclib; Idarubicin
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Sponsors FORMA Therapeutics; Novo Nordisk

Most Recent Events

  • 01 Apr 2025 Results(n=15) evaluating the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine published in the British Journal of Haematology.
  • 10 Dec 2024 Results (n=147) assessing efficacy data with up to five years of follow-up presented at the 66th American Society of Hematology Annual Meeting and Exposition
  • 05 Nov 2024 According to a Rigel Pharmaceuticals media release, data from the study will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, California and virtually.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top